CL2023003562A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents

Anticuerpos y composiciones anti-nkg2a

Info

Publication number
CL2023003562A1
CL2023003562A1 CL2023003562A CL2023003562A CL2023003562A1 CL 2023003562 A1 CL2023003562 A1 CL 2023003562A1 CL 2023003562 A CL2023003562 A CL 2023003562A CL 2023003562 A CL2023003562 A CL 2023003562A CL 2023003562 A1 CL2023003562 A1 CL 2023003562A1
Authority
CL
Chile
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
cancer
Prior art date
Application number
CL2023003562A
Other languages
English (en)
Spanish (es)
Inventor
Westh Hansen Randi
Katharina Uhlenbrock Franziska
Dietrich Nikolaj
Worsaae Anne
Monrad Grandal Michael
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2023003562A1 publication Critical patent/CL2023003562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2023003562A 2021-06-01 2023-11-29 Anticuerpos y composiciones anti-nkg2a CL2023003562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01

Publications (1)

Publication Number Publication Date
CL2023003562A1 true CL2023003562A1 (es) 2024-07-12

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003562A CL2023003562A1 (es) 2021-06-01 2023-11-29 Anticuerpos y composiciones anti-nkg2a

Country Status (17)

Country Link
US (2) US12012450B2 (https=)
EP (1) EP4347651A1 (https=)
JP (1) JP2024520577A (https=)
KR (1) KR20240016991A (https=)
CN (1) CN117460748A (https=)
AR (1) AR126001A1 (https=)
AU (1) AU2022286617A1 (https=)
BR (1) BR112023024772A2 (https=)
CA (1) CA3222040A1 (https=)
CL (1) CL2023003562A1 (https=)
CO (1) CO2023015982A2 (https=)
IL (1) IL308695A (https=)
MX (1) MX2023014320A (https=)
PE (1) PE20240372A1 (https=)
PH (1) PH12023553123A1 (https=)
TW (1) TW202313683A (https=)
WO (1) WO2022253805A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
US10329348B2 (en) * 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途

Also Published As

Publication number Publication date
US20220389100A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US12012450B2 (en) 2024-06-18
CN117460748A (zh) 2024-01-26
AU2022286617A1 (en) 2023-12-21
CO2023015982A2 (es) 2024-01-15
PE20240372A1 (es) 2024-03-05
EP4347651A1 (en) 2024-04-10
AR126001A1 (es) 2023-08-30
CA3222040A1 (en) 2022-12-08
WO2022253805A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
MX2023014320A (es) 2023-12-13
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
US20240294638A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
CL2023003562A1 (es) Anticuerpos y composiciones anti-nkg2a
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CL2024002093A1 (es) Anticuerpos anti-cd73.
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CO2026004333A2 (es) Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
MX2018008939A (es) Anticuerpos anti-factor de la coagulacion xi.
CL2021001685A1 (es) Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.